CANDIDATE LABORATORY MARKERS OF LONG-TERM FUNCTIONING OF THE DUCTUS ARTERIOSUS IN EXTREMELY LOW BIRTH WEIGHT INFANTS
Main Article Content
Abstract
Objective. Pathogenetic relationships between clinical, biochemical blood parameters and long-term functioning of the patent ductus arteriosus (PDA) in newborns with extremely low birth weight (ELBW).
Purpose of the study – to identify candidate markers of a functioning hemodynamically significant patent ductus arteriosus in newborns with ELBW from among routinely measured clinical and biochemical blood parameters.
Methods. Observational, retrospective, case / control study; the grouping factor was a long-term hemodynamically significant patent ductus arteriosus. The following indicators were analyzed: hemoglobin, leukocyte intoxication index, platelets, potassium, sodium, calcium, glucose – comparison of the studied indicators between the two groups, as well as within each group was carried out in three periods of life: 1-2 weeks, 3-4 week and 2nd month of life.
Results. Statistically significant differences between the compared groups of newborns were found in the period 1-2 weeks of life in terms of hemoglobin, platelets and potassium levels, which is pathogenetically substantiated. The dynamics of potassium, sodium and leukocyte intoxication index levels obtained by us within the studied groups also indirectly indicates the role of hypoxia and inflammation in the process of PDA closure in newborns with ELBW.
Conclusions. The found additional markers can be used to predict long-term functioning PDA and select the optimal management tactics for newborns with ELBW. There is a pathogenetic relationship between the level of hemoglobin, platelets, potassium with long-term persistent PDA.
Keywords
Article Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
Ruoss JL, Bazacliu C, Giesinger RE, McNamara PJ. Patent ductus arteriosus and cerebral, cardiac, and gut hemodynamics in premature neonates. Semin Fetal Neonatal Med. 2020; 25(5): 101-120
Rios DR, Martins FF, Khuffash AE, Weisz DE, Giesinger RE, Namara PJ. Early role of the atrial-level communication in premature infants with patent ductus arteriosus. J Am Soc Echocardiogr. 2021; 34(4): 423-432. doi: 10.1016/j.echo.2020.11.008
Segar JL. A physiological approach to fluid and electrolyte management of the preterm infant: Review. J Neonatal Perinatal Med. 2020; 13(1): 11-19. doi: 10.3233/NPM-190309
Clerx M, Mirams GR, Rogers AJ, Narayan SM, Giles WR. Immediate and delayed response of simulated human atrial myocytes to clinically-relevant hypokalemia. Front Physiol. 2021; 12: 103-112. 651162. doi: 10.3389/fphys.2021.651162
Karabulut B, Arcagök BC, Simsek A. Utility of the Platelet-to-Lymphocyte Ratio in Diagnosing and Predicting Treatment Success in Preterm Neonates with Patent Ductus Arteriosus. Fetal Pediatr Pathol. 2021; 40(2): 103-112. doi: 10.1080/15513815.2019.1686786
Druzhba AV, Mostovoy AV, Karpova AL, Ievkov SA. Influence of hemoglobin and hematocrit levels on the successful medical treatment of patent ductus arteriosus in premature infants. Neonatology: news, opinions, education. 2018; 6(4): 9-15. Russian (Дружба А.В., Мостовой А.В., Карпова А.Л., Иевков С.А. Влияние уровня гемоглобина и гематокрита на успех медикаментозного закрытия артериального протока у недоношенных новорожденных //Неонатология: новости, мнения, обучение. 2018. Т. 6, № 4. С. 9-15.) doi: 10.24411/2308-2402-2018-14001
Lorigo M, Oliveira N, Cairrao E. Clinical importance of the human umbilical artery potassium channels. Cells. 2020; 9(9): 1956. https://doi.org/10.3390/cells9091956
Sallmon H, Weber SC, Dirks J, et al. Association between platelet counts before and during pharmacological therapy for patent ductus arteriosus and treatment failure in preterm infants. Front Pediatr. 2018; 6: 41